Introduction {#S1}
============

The accumulation of macrophages in the obese adipose tissue (AT) and their polarization into classically activated (inflammatory) M1 cells are critically involved in AT inflammation and metabolic dysregulation in obesity[@R1],[@R2]. In contrast to the extensively studied chemokine-driven monocyte/macrophage recruitment to the AT[@R3],[@R4],[@R5], little information exists about mechanisms contributing to macrophage retention in the AT[@R6]. The close proximity of inflammatory macrophages with adipocytes in the obese AT, especially in regions designated "crown-like structures"[@R1], suggests that direct macrophage-adipocyte adhesive interactions may constitute a macrophage retention mechanism in the AT. Direct adhesive interactions between immune and other cell types are largely mediated by leukocyte integrins[@R7]. However, whether integrin-dependent adhesion mediates macrophage retention in the obese AT and contributes to inflammation-related metabolic dysregulation in obesity has not been yet investigated.

Besides serving as energy-storage organ, the white AT plays a homeostatic role in energy dissipation. The energy-dispensing function of the AT is mediated by upregulation of uncoupling protein-1 (UCP1), which uncouples oxidative phosphorylation from ATP synthesis and thereby induces thermogenic activity in the white AT[@R8],[@R9],[@R10]. This function is largely attributed to a recently identified subtype of "beige" adipocytes. These cells inducibly express UCP1, principally in response to cold exposure, and thus share functional properties of brown adipocytes, e.g., thermogenic capacity[@R9],[@R11],[@R12],[@R13]. As beige fat also exists in humans[@R13], beige adipogenesis represents a potentially important therapeutic target in obesity[@R13]. Beige adipogenesis may derive from generation of beige adipocytes from committed progenitors but also from transdifferentiation of white adipocytes into beige cells[@R9]. Interestingly, cells of type 2 immunity stimulate beige adipogenesis in the lean AT[@R14].

Intriguingly, the expression of UCP1 and the energy-dissipating activity of the white AT are diminished in adiposity[@R15],[@R16],[@R17], although the mechanistic underpinnings involved remain obscure. Exacerbated inflammation, including a shift from M2 towards a predominantly pro-inflammatory M1 macrophage state, is a hallmark of obese white AT[@R1],[@R2]. Yet, little evidence exists that inflammation can impede thermogenic beige adipogenesis in obesity[@R18]. Hypothetically, inflammatory macrophages in the obese AT may secrete factors that interfere with beige adipogenesis. Alternatively or additionally, given the proximity of macrophages and adipocytes in obese AT, adhesive interactions between these two cell types could conceivably contribute to inhibition of beige adipogenesis. This hypothesis was confirmed in the present study, which demonstrated that the interaction between α~4~ integrin[@R7] on M1-polarized inflammatory macrophages and its counter-receptor vascular cell adhesion molecule-1 (VCAM-1) on adipocytes in the obese AT initiates a self-sustained inflammatory cycle that downregulates UCP1 expression in adipocytes in an extracellular signal-regulated kinase (Erk)--dependent manner. Conversely, genetic or pharmacological blockage of α~4~ integrin led to elevated beige adipogenesis and prevented metabolic dysregulation of the obese AT.

Results {#S2}
=======

Macrophage-adipocyte adhesive interactions in obese AT {#S3}
------------------------------------------------------

To study macrophage-adipocyte interactions in the obese AT, we focused on integrin adhesion receptors involved in leukocyte trafficking and cell-cell adhesion[@R19]. In this regard, the integrins α~4~β~1~ and α~L~β~2~ are major players mediating the adhesive functions of monocytes and macrophages by recognizing their counter-receptors VCAM-1 and ICAM-1, respectively, on target cells[@R7],[@R20]. We performed adoptive transfer experiments to identify those integrin receptors involved in macrophage accumulation in obese AT. To bypass embryonic lethality of α~4~ integrin (*Itga4*) deletion, we engaged mice with inducible hematopoietic *Itga4* deficiency[@R21], which were generated by breeding *Itga4*^f/f^ mice with Mx1-Cre-transgenic mice, in which Cre activity is induced by poly I:C[@R21]. Cre-recombinase is induced in several tissues in Mx1-Cre-transgenic mice, however, the main Cre-recombinase activity is shown in hematopoietic system and liver[@R22],[@R23]. Itga4 is predominantly expressed in hematopoietic cells[@R21],[@R24],[@R25], whereas *Itga4* expression in isolated liver parenchymal cells was comparably very low (data not shown). After poly I:C administration, robust reduction of α~4~ integrin expression in bone marrow-isolated monocytes from mice with inducible genetic excision of *Itga4* (hereafter Cre^+^α~4~^f/f^) was observed ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}), consistent with a previous report involving Mx1-Cre^+^*Itga4*^f/f^ mice[@R21].

For adoptive transfer, dye-labeled bone marrow-isolated CD11b^+^ monocytes from Cre^+^α~4~^f/f^ mice[@R21], and monocytes from littermate *Itga4*--sufficient control mice (Cre^--^α~4~^f/f^), or monocytes from α~L~ integrin--deficient and --proficient mice[@R26] were simultaneously injected, at a 1:1 competitive fashion, into diet-induced obese wild-type mice. Seven days thereafter, we analyzed accumulation and retention of administered cells in the AT; the majority of adoptively transferred monocytes that had accumulated in the obese AT had acquired macrophage markers. Accumulation of macrophages in both obese visceral and inguinal subcutaneous AT (VAT and SAT, respectively) was dependent on α~4~ but not α~L~ integrin expression ([Fig. 1a](#F1){ref-type="fig"} and data not shown). The reduced accumulation of *Itga4*-deficient macrophages in the SAT and VAT of obese wild-type mice, as compared to *Itga4*-sufficient macrophages, was accompanied by significantly enhanced numbers of *Itga4*-deficient monocytes/macrophages in the draining lymph nodes of both SAT and VAT ([Fig. 1b](#F1){ref-type="fig"}). These findings suggested that α~4~ integrin-deficient macrophages had egressed from SAT and VAT, and hence had reduced retention therein. In contrast, T lymphocyte accumulation in the obese SAT or VAT was independent of their α~4~ integrin expression ([Fig. 1c](#F1){ref-type="fig"}).

To further elucidate the role of α~4~ integrin for macrophage retention in the obese AT, we analyzed the expression of VCAM-1, the major counter-receptor of α~4~β~1~[@R27]. Constitutive expression of *Vcam1* was observed in the lean SAT and VAT. *Vcam1* expression was massively upregulated in both SAT and VAT upon diet-induced obesity (DIO) with high-fat diet (HFD) ([Fig. 1d](#F1){ref-type="fig"}). The AT upregulation of *Vcam1* was predominantly attributed to its increased expression in adipocytes rather than in endothelial cells ([Fig. 1d](#F1){ref-type="fig"}). Adipocyte *Vcam1* expression in the obese SAT was considerably higher than endothelial *Vcam1* expression ([Fig. 1e](#F1){ref-type="fig"}). VCAM-1 was detectable in both 3T3-L1 and primary adipocytes, and its expression was upregulated upon treatment with tumor necrosis factor (TNF) or palmitate, both being hallmark factors of the obese AT environment[@R1],[@R4] ([Fig. 1f](#F1){ref-type="fig"} and data not shown). We therefore hypothesized that the interaction between α~4~ integrin and VCAM-1 could mediate adhesion of macrophages to adipocytes in the obese AT. Indeed, adhesion of bone marrow-derived mononuclear cells onto adipocytes *in vitro* was blocked by antibody to VCAM-1 but not antibody to ICAM-1 ([Fig. 1g](#F1){ref-type="fig"}). Consistently, α~4~ integrin-deficient mononuclear cells displayed reduced adhesion to adipocytes, compared to α~4~ integrin-proficient cells ([Fig. 1h](#F1){ref-type="fig"}). Together, macrophage-adipocyte adhesion is dependent on the α~4~ integrin--VCAM-1 interaction and α~4~ integrin mediates retention of macrophages in the obese AT.

*Itga4* deficiency reduces metabolic dysfunction in DIO {#S4}
-------------------------------------------------------

We then determined whether the α~4~ integrin-mediated adhesive interaction between macrophages and adipocytes in the obese AT contributes to DIO-related metabolic dysregulation. Mice lacking α~4~ integrin (Cre^+^α~4~^f/f^) and littermate control α~4~ integrin-proficient mice (Cre^--^α~4~^f/f^) were fed a HFD. By flow cytometry we observed robust deletion of α~4~ integrin in circulating monocytes and macrophages from the AT of Cre^+^α~4~^f/f^ mice ([Supplementary Fig. 1b,c](#SD1){ref-type="supplementary-material"}). Obese Cre^+^α~4~^f/f^ and Cre^--^α~4~^f/f^ mice displayed no differences in terms of body weight gain, fat mass or liver, SAT or VAT weight ([Fig. 2a,b](#F2){ref-type="fig"} and [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Similarly, HFD-fed Cre^+^α~4~^f/f^ mice displayed no significant changes in the adipocyte size of VAT or SAT as compared to Cre^--^α~4~^f/f^ mice ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). However, Cre^+^α~4~^f/f^ mice in DIO displayed improved insulin sensitivity and reduced glucose concentrations (though unaltered triglyceride or cholesterol concentrations) as compared to Cre^--^α~4~^f/f^ mice ([Fig. 2c,d](#F2){ref-type="fig"} and [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). No difference in insulin sensitivity between Cre^+^α~4~^f/f^ and Cre^--^α~4~^f/f^ mice under normal diet conditions was observed (data not shown).

To study macrophage accumulation and retention in the AT of obese Cre^+^α~4~^f/f^ and Cre^--^α~4~^f/f^ mice, we performed immunofluorescence staining (using caveolin-1 and F4/80 to stain adipocytes[@R6],[@R28] and macrophages, respectively) followed by confocal microscopy of the obese SAT from Cre^+^α~4~^f/f^ and Cre^--^α~4~^f/f^ mice. We found that the abundance of crown-like structures (CLS) as well as of non-CLS-associated macrophages in proximity to adipocytes was reduced in the obese AT as a result of *Itga4* deletion ([Fig. 2e,f](#F2){ref-type="fig"}). These findings were independently verified by immunohistochemistry analysis of F4/80-labeled macrophages and histological quantification, which demonstrated a significant reduction in CLS numbers and numbers of non-CLS-associated macrophages in contact with adipocytes in obese SAT resulting from loss of α~4~ integrin expression ([Supplementary Fig. 3a,b](#SD1){ref-type="supplementary-material"}).

To further substantiate our hypothesis that α~4~ integrin mediates macrophage-adipocyte interactions in the obese AT, we quantified the area of contact of macrophages to adipocytes, as a measure of macrophage-adipocyte adhesion. This analysis revealed that macrophages had reduced contact to adipocytes as a result of *Itga4* deletion ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Moreover, 3D-reconstruction of macrophage-adipocyte interactions verified the decreased contact of macrophages to and spreading on adipocytes in Cre^+^α~4~^f/f^ mice, compared to littermate Cre^--^α~4~^f/f^ mice ([Supplementary Fig. 4a-d](#SD1){ref-type="supplementary-material"}). These effects were likely independent of netrin-1, which contributes to macrophage retention in the obese AT[@R6], since *Itga4* deletion did not affect *Ntn1* expression in the obese SAT or VAT ([Supplementary Fig. 5a-b](#SD1){ref-type="supplementary-material"}).

To characterize the inflammatory milieu of the SAT and VAT of obese Cre^+^α~4~^f/f^ and Cre^--^α~4~^f/f^ mice, we studied the abundance of pro-inflammatory M1-like macrophages and of M2-like macrophages, defined by flow cytometry as F4/80^+^CD11b^+^iNOS^+^CD206^--^ and F4/80^+^CD11b^+^iNOS^--^CD206^+^, respectively. We found significantly lower numbers of M1 macrophages in both SAT and VAT of obese Cre^+^α~4~^f/f^ mice, as compared to their littermate controls, while the numbers of M2 macrophages in the obese AT remained unaffected by *Itga4* deletion ([Fig. 2g,h](#F2){ref-type="fig"}). These findings were confirmed by flow cytometry staining of inflammatory macrophages as F4/80^+^CD11b^+^CD11c^+^CD206^--^ and M2-like macrophages as F4/80^+^CD11b^+^CD11c^--^CD206^+^ (data not shown); CD11c has been previously used as a marker of inflammatory AT macrophages[@R29]. Furthermore, the decreased M1 macrophage abundance in both VAT and SAT of Cre^+^α~4~^f/f^ mice, compared to Cre^--^α~4~^f/f^ mice, was confirmed by the reduced numbers of TNF-expressing macrophages ([Fig. 2i,j](#F2){ref-type="fig"}). In wild-type mice, M1-like macrophages from obese SAT and VAT displayed higher expression of α~4~ integrin, as compared to M2-like macrophages ([Fig. 2k](#F2){ref-type="fig"}). These data suggest that α~4~ integrin mediates direct macrophage adhesion to VCAM-1--expressing adipocytes and thereby inflammatory macrophage retention within the obese AT, AT inflammation and insulin resistance.

Cre^+^α~4~^f/f^ mice in DIO have enhanced beige adipogenesis {#S5}
------------------------------------------------------------

To understand the improved metabolic phenotype of α~4~ integrin-deficient mice, we performed metabolic cage analysis. Cre^+^α~4~^f/f^ mice in DIO displayed enhanced energy expenditure, as compared to littermate Cre^--^α~4~^f/f^ mice ([Fig. 3a](#F3){ref-type="fig"}) although no difference was detected in respiratory exchange ratio (data not shown). The absence of body weight difference in DIO between Cre^--^α~4~^f/f^ and Cre^+^α~4~^f/f^ mice, despite the increased energy expenditure of Cre^+^α~4~^f/f^ mice, could be attributed to increased food intake by these mice ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}).

To elucidate the finding of increased energy expenditure in obese Cre^+^α~4~^f/f^ mice, we assessed the expression of thermogenic genes in white or brown AT. Both mRNA and protein expression of the major thermogenic gene *Ucp1*, and mRNA expression of brown fat identity genes (*Cidea*, *Cox8b*) were upregulated in SAT of Cre^+^α~4~^f/f^ mice ([Fig. 3b,c](#F3){ref-type="fig"}). Consistently, cold (4°C)-challenged Cre^+^α~4~^f/f^ mice sustained a higher core temperature, accompanied by enhanced expression of the key thermogenic protein UCP1, as compared to littermate control mice ([Fig. 3d,e](#F3){ref-type="fig"}). Immunohistochemical analysis for UCP1 revealed increased presence of beige adipogenesis areas in SAT of cold-exposed Cre^+^α~4~^f/f^ compared to Cre^--^α~4~^f/f^ mice ([Fig. 3f](#F3){ref-type="fig"}). Although *Itga4* deletion enhanced beige adipogenesis in the SAT of obese mice, it had no effect on thermogenic gene expression in the VAT, or on thermogenic gene expression and UCP1 protein abundance, as assessed by immunohistochemistry, in the brown AT (BAT) ([Supplementary Fig. 6b,c](#SD1){ref-type="supplementary-material"}). To address this difference, we compared SAT and BAT for *Vcam1* expression and found it much higher in the adipocytes of the obese SAT than in those from obese BAT ([Fig. 3g](#F3){ref-type="fig"}). This finding provides an explanation as to why *Itga4* deletion predominantly increased thermogenic beige adipogenesis in obese SAT, without affecting thermogenic gene expression in BAT. Therefore, the increased energy dissipation activity of obese Cre^+^α~4~^f/f^ mice derived from a more thermogenic SAT.

Pharmacologic α4 integrin inhibition in obesity {#S6}
-----------------------------------------------

As increased beige adipogenesis of the white AT is linked to improved metabolic control, approaches to stimulate white fat beiging have emerged as an attractive anti-obesity therapeutic strategy[@R30]. We therefore assessed the therapeutic potential of pharmacologic α~4~ integrin inhibition in wild-type mice that received an α~4~ integrin-inhibitor, which preferentially blocks α~4~β~1,~ or vehicle control via mini-osmotic pumps for 6 weeks after establishment of DIO. DIO mice receiving the α~4~-inhibitor exhibited improved insulin sensitivity and lower concentrations of serum insulin, glucose and cholesterol as compared to control-treated mice ([Fig. 4a-c](#F4){ref-type="fig"}). Confocal microscopy analysis of obese SAT revealed that α~4~ integrin inhibition reduced the abundance of macrophages in contact with adipocytes ([Fig. 4d](#F4){ref-type="fig"}). Histological quantification demonstrated that numbers of both CLS and of non-CLS-associated macrophages in proximity to adipocytes in the SAT were significantly decreased by α~4~ integrin blockade ([Fig. 4e](#F4){ref-type="fig"}). Moreover, flow cytometry analysis revealed that the abundance of M1-like macrophages (defined as F4/80^+^CD11b^+^iNOS^+^CD206^--^) was significantly lower in the SAT of obese mice receiving the α~4~-inhibitor, as compared to control treated mice, whereas the numbers of M2-like macrophages in the obese SAT remained unaffected by α~4~ integrin blockade ([Fig. 4f](#F4){ref-type="fig"}). Furthermore, α~4~ integrin inhibition in DIO mice led to enhanced beige adipogenesis of the SAT, as evidenced by elevated mRNA and protein expression of UCP1 in the SAT ([Fig. 5a,b](#F5){ref-type="fig"}) but not in VAT (data not shown).

The α~4~-inhibitor was also tested in ob/ob mice, a model of genetically induced obesity. The α~4~-inhibitor--treated ob/ob mice displayed improved insulin sensitivity, which was accompanied by enhanced thermogenesis, increased UCP1 protein expression, and ameliorated inflammatory macrophage accumulation in the SAT ([Supplementary Fig. 7a-d](#SD1){ref-type="supplementary-material"}). Together, our findings suggest that functional inactivation of α~4~ integrin-mediated macrophage interactions in obese AT ameliorates obesity-related metabolic dysregulation via improved beige adipogenesis.

To substantiate the mechanism of action of pharmacologic α~4~β~1~ inhibition, we exposed α~4~-inhibitor-- or vehicle--treated DIO mice to thermoneutrality conditions (30°C), wherein UCP1 is functionally incompetent[@R12],[@R14]. In contrast to the improved insulin sensitivity and enhanced *Ucp1* expression as a result of α~4~-inhibitor treatment in mice kept under 22°C, these differences were largely abolished in thermoneutrality ([Fig. 5c-e](#F5){ref-type="fig"}). In thermoneutrality, a slight increase in *Ucp1* gene expression, which was however not significant, was observed in α~4~-inhibitor--treated DIO mice, compared to control-treated mice ([Fig. 5e](#F5){ref-type="fig"}). The M1-macrophage content was reduced in both SAT and VAT of the α~4~-inhibitor--treated mice under thermoneutral conditions ([Fig. 5f](#F5){ref-type="fig"}). Hence, the α~4~-inhibitor failed to improve insulin sensitivity or beige adipogenesis under thermoneutral conditions despite reducing macrophage accumulation, suggesting that UCP1 is crucially involved in the mechanism whereby pharmacologic α~4~ inhibition promotes beige adipogenesis of white AT and prevents obesity-related metabolic dysregulation.

Macrophage-adipocyte adhesion inhibits UCP1 expression {#S7}
------------------------------------------------------

Recent studies suggested that alternatively activated M2 macrophages, promote beige adipogenesis in the lean AT in a paracrine fashion[@R14]. However, whether M1-like inflammatory macrophages can conversely mediate proactive inhibition of beige adipogenesis has not been hitherto demonstrated, although it is strongly suggested by our findings. Consistent with previous findings[@R16],[@R18],[@R31], the expression of UCP1 in the obese SAT was reduced at mRNA and protein level, as compared to the lean SAT (data not shown), implying that the predominance of inflammatory macrophages in the obese SAT correlates with inhibition of beige adipogenesis. To conclusively demonstrate this concept and to dissect its mechanistic underpinnings, we performed macrophage-primary adipocyte co-cultures. The adipocytes used were generated from pre-adipocytes isolated from the stromal vascular fraction (SVF) of wild-type mouse SAT that maintain their ability to express beige-related genes including *Ucp1^8^*. White and beige adipocytes have bidirectional interconversion properties[@R9],[@R13],[@R32], likely because they originate from PDGFRα^+^ bipotent precursors[@R33]. Norepinephrine and triiodothyronine (T3) were added to primary adipocytes prior to adipocyte-macrophage co-cultures performed here, in order to drive a beige-like profile and activation of *Ucp1* expression[@R34] ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). For M1-like inflammatory macrophages, we used GM-CSF-cultured bone marrow-derived macrophages (BMDMs) that were stimulated with lipopolysaccharide (LPS) or obese SAT-derived, LPS- plus interferon-γ (IFN-γ)-stimulated macrophages[@R35],[@R36]. When adipocytes were cultured in direct contact (same well) with pro-inflammatory M1-like BMDMs, the norepinephrine/T3-stimulated adipocyte *Ucp1* expression was significantly decreased ([Fig. 6a](#F6){ref-type="fig"}). Similar results were obtained when adipocytes were cultured in direct contact with SAT-derived pro-inflammatory, LPS plus IFN-γ-stimulated macrophages ([Fig. 6b](#F6){ref-type="fig"}). Consistently, *Itga4* deletion was associated with increased thermogenic *Ucp1* expression in the SAT, which, among fat pads with thermogenic potential (SAT and BAT), was the one with the highest adipocyte VCAM-1 expression in obesity. The inhibition of *Ucp1* expression mediated by the direct cell-cell contact of inflammatory macrophages with adipocytes was reversed by the α~4~-inhibitor, which did not affect adipocyte expression of this thermogenic gene in the absence of macrophages ([Fig. 6a,b](#F6){ref-type="fig"}). These data suggest that the inhibitory effect of inflammatory macrophages on beige adipogenesis requires direct α~4~ integrin-dependent cell-to-cell adhesive interactions.

We generated M2-like macrophages by stimulating lean SAT-derived macrophages with interleukin-4 (IL-4) and co-cultured them with differentiated adipocytes. M2-like macrophages promoted adipocyte *Ucp1* expression when cultured with adipocytes in both direct contact and non-contact (transwell) mode. Under both co-culture conditions, α~4~ integrin inhibition did not affect the M2-like macrophage-triggered *Ucp1* expression in adipocytes ([Fig. 6c,d](#F6){ref-type="fig"}).

Recent studies have highlighted the opposing roles of the p38 mitogen-activated protein kinase (p38 MAPK)[@R37] and Erk signaling pathways[@R38],[@R39] in beige adipogenesis and UCP1 regulation, mediating stimulatory or inhibitory effects, respectively. We found that direct co-culture of inflammatory macrophages with primary adipocytes resulted in downregulation of phospho-p38 and upregulation of phospho-Erk content in adipocytes ([Fig. 6e,f](#F6){ref-type="fig"}), thereby providing a mechanistic basis for the inhibitory effect of inflammatory macrophages on adipocyte *Ucp1* expression. The reduction of *Ucp1* expression by the presence of M1-like macrophages was reversed when adipocytes were pre-treated with an Erk inhibitor ([Fig. 6g](#F6){ref-type="fig"}). Next, we sought to determine whether the α~4~ integrin--dependent inhibitory effect of inflammatory macrophages on beige adipogenesis was driven by regulation of the phospho-p38 and phospho-Erk pathways. In support of this notion, the abundance of phospho-p38 increased, whereas phospho-Erk decreased when the direct contact between adipocytes and inflammatory macrophages was blocked by the α~4~-inhibitor ([Fig. 6h,i](#F6){ref-type="fig"}).

Besides the ability of white adipocytes for induction of UCP1 expression[@R9],[@R10],[@R40], adipocyte progenitors can also differentiate to beige adipocytes[@R33],[@R41]. We, therefore, assessed whether direct contact with pro-inflammatory macrophages could affect *Ucp1* expression also in adipocyte progenitors. First, we found that PDGFRα^+^Sca-1^+^ adipocyte progenitors from SAT of obese mice displayed significantly increased expression of *Vcam1* compared to adipocyte progenitors from lean mice ([Fig. 6j](#F6){ref-type="fig"}). Moreover, TNF significantly increased *Vcam1* expression in adipocyte progenitors ([Fig. 6k](#F6){ref-type="fig"}). In addition, when adipocyte progenitors were cultured in the presence of pro-inflammatory M1-like macrophages (in a direct cell-to-cell contact assay), their *Ucp1* expression was significantly decreased in a manner dependent on the α~4~β~1~--VCAM-1 interaction ([Fig. 6l](#F6){ref-type="fig"}).

We next assessed whether the direct α~4~β~1~--VCAM-1 interaction between macrophages and adipocytes could also affect inflammatory activation in macrophages, thereby leading to a self-sustained cycle of persistent AT inflammation. Culture of macrophages on VCAM-1 pre-coated plates enhanced TNF expression ([Fig. 7a,b](#F7){ref-type="fig"}), which is a cardinal marker of M1 macrophage polarization[@R2],[@R35],[@R42]. The VCAM-1-dependent upregulation of TNF in macrophages was abrogated in the presence of the α~4~-inhibitor ([Fig. 7a](#F7){ref-type="fig"}) or in α~4~ integrin-deficient macrophages ([Fig. 7b](#F7){ref-type="fig"}). Consistently, α~4~ integrin inhibition or deficiency in macrophages prevented the enhanced TNF expression in macrophages resulting from direct cell-to-cell contact with adipocytes ([Fig. 7c,d](#F7){ref-type="fig"}). Thus, the α~4~ integrin-dependent crosstalk of macrophages with adipocytes is bidirectional, promoting inflammatory activation in the former and blocking beige adipogenesis in the latter.

We then studied whether inflammatory macrophages could further contribute to inhibition of beige adipogenesis by upregulating VCAM-1 in the adipocyte compartment. Since TNF could enhance VCAM-1 in adipocytes and TNF itself was upregulated by the direct macrophage-adipocyte contact, we explored whether macrophage-derived TNF could stimulate VCAM-1 expression in adipocytes. We therefore performed non-contact (transwell) macrophage-adipocyte co-cultures. We observed upregulation of VCAM-1 in adipocytes upon co-culture with SAT-derived M1-like inflammatory macrophages. This paracrine increase in adipocyte VCAM-1 expression by inflammatory macrophages was inhibited by an antibody against TNF ([Fig. 7e](#F7){ref-type="fig"}). In contrast, adipocyte VCAM-1 expression was not affected upon co-culture in transwells with SAT-derived M2-like macrophages both in the absence or presence of the α~4~ integrin inhibitor ([Fig. 7f](#F7){ref-type="fig"}).

Together, the α~4~ integrin--dependent adhesive macrophage-adipocyte interaction promotes a self-sustained inflammatory loop in obese AT, which involves inflammatory activation of macrophages, resulting in enhanced TNF production that further upregulates VCAM-1 in adipocytes. The direct α~4~ integrin--dependent macrophage-adipocyte interaction also inhibits UCP1 expression, which may contribute to reduced beige adipogenesis in obesity.

Macrophage-adipocyte interactions in the human system {#S8}
-----------------------------------------------------

We then determined whether the adhesive α~4~ integrin--VCAM-1-dependent inflammatory macrophage-adipocyte interaction could also operate in the human system. At first, we observed an inverse correlation between the expression of *UCP1* and *VCAM1* in SAT samples obtained from individuals during abdominal surgery ([Fig. 7g](#F7){ref-type="fig"}). We also found that expression of *VCAM1* was increased in human adipocytes (differentiated from pre-adipocytes) upon stimulation with TNF or palmitate ([Fig. 7h](#F7){ref-type="fig"}). Moreover, adhesion of human M1-like pro-inflammatory macrophages to adipocytes was partially inhibited by the α~4~-inhibitor ([Fig. 7i](#F7){ref-type="fig"}). Co-culture of inflammatory macrophages with primary adipocytes (in a direct cell-to-cell contact fashion) reduced *UCP1* expression in the latter in a manner dependent on α~4~β~1~--VCAM-1-mediated adhesion ([Fig. 7j](#F7){ref-type="fig"}). These data suggest that direct macrophage-adipocyte interactions may downregulate *UCP1* expression in human SAT as well.

Discussion {#S9}
==========

Beige adipogenesis linked with thermogenic UCP1 expression is a homeostatic function of the lean AT promoting energy expenditure[@R43]. In human and murine obesity, beige adipogenesis becomes dysfunctional and this phenomenon is associated with enhanced AT inflammation[@R15],[@R17],[@R18],[@R33],[@R44],[@R45]. Here, we established a self-sustained loop linking AT inflammation and inflammatory macrophage retention with impaired beige adipogenesis in obesity. Specifically, α~4~ integrin-mediated adhesion of inflammatory macrophages to VCAM-1, the expression of which is augmented in adipocytes (and their progenitors) in obesity, inhibits thermogenic UCP1 expression via an Erk-dependent way.

Enhanced abundance of inflammatory macrophages in the obese AT may depend on integrins, such as α~4~β~1~, increased expression of monocyte-attracting chemokines[@R1],[@R20],[@R27],[@R29], or on local macrophage expansion[@R44]. It is conceivable that the herein identified α~4~ integrin-mediated macrophage retention mechanism might also facilitate AT macrophage expansion[@R44]. We found that TNF, which is elevated in the obese AT[@R1],[@R46], upregulates VCAM-1 expression in adipocytes and their progenitors, thereby promoting direct α~4~ integrin--VCAM-1-dependent adhesive interactions with macrophages. This interaction promotes retention of macrophages in the obese AT and drives further pro-inflammatory M1-like polarization, including increased TNF production, thereby further enhancing adipocyte VCAM-1 expression and sustaining the direct macrophage-adipocyte interaction, hence perpetuating AT inflammation. Importantly, the α~4~ integrin-dependent adhesion of macrophages to adipocyte VCAM-1 inhibits UCP1 expression and thus beige adipogenesis, thereby establishing a paramount paradigm of inflammation-driven metabolic dysfunction of obese AT.

In this regard, the α~4~ integrin-mediated interaction of inflammatory macrophages with adipocytes downregulated p38 MAPK and upregulated Erk signaling in the latter cells, leading to downregulation of UCP1, in accordance with recent reports[@R37],[@R38],[@R39]. Furthermore, Erk signaling in adipocytes promotes insulin resistance and diabetogenic actions via regulation of PPARγ function[@R47]. Therefore, the α~4~ integrin--VCAM-1-mediated mechanism dissected here may regulate further detrimental actions of Erk signaling in adipocytes.

Our findings are consistent with a previous study, which utilized α~4~(Y991A) knock-in mice, and demonstrated that inhibition of α~4~ integrin signaling ameliorates DIO-related metabolic dysfunction[@R20]. However, our work additionally introduces a new concept that α~4~ integrin-dependent direct adhesion of inflammatory macrophages to adipocytes inhibits UCP1 expression and reveals a hitherto unknown self-sustained cycle linking AT inflammation with impaired beige adipogenesis in obesity.

VCAM-1 expression analysis is usually confined to predominantly the vascular endothelium and hematopoietic cells[@R48],[@R49]. We found that enhanced VCAM-1 expression in the obese AT[@R50] predominantly derives from adipocytes. Moreover, the most prominent adipocyte VCAM-1 expression was observed in the SAT (rather than the VAT or the BAT), thereby potentially explaining why genetic or pharmacologic α~4~ integrin inhibition primarily affected UCP1 expression and beige adipogenesis in this particular fat pad. The dissected α~4~ integrin-dependent adhesive interaction may regulate beige adipogenesis in the human system, as supported by the inverse correlation between human SAT VCAM-1 and UCP1 expression. Noteworthy, although multiple papers have described adhesive leukocyte-endothelial interactions that mediate inflammatory cell recruitment, little knowledge exists on adhesive mechanisms between macrophages and tissue resident cells, as well as the functional consequences thereof for the local tissue environment. In this context, a new pathogenic principle arising from this work involves direct adhesive interactions between inflammatory cells and parenchymal cells. This novel disease-promoting mechanism may underlie several other chronic inflammatory disorders and is therapeutically important, as it is amenable to intervention. The mechanism presented here is of therapeutic relevance, since we have pinpointed α~4~ integrin as a potential target for anti-obesity intervention. Pharmacologic inhibition of α~4~ integrin promoted systemic insulin sensitivity by stimulating beige adipogenesis; such a therapeutic strategy has not been yet harnessed by current antidiabetic drugs and may merit detailed investigation in further preclinical settings.

Online Methods {#S10}
==============

Animal studies {#S11}
--------------

Mx1-cre^+^*Itga4*^flox/flox^ mice (Cre^+^α~4~^f/f^) were previously described[@R21]. To induce excision of α~4~ integrin, Cre-recombinase was induced in male Cre^+^α~4~^f/f^ mice by 3 intraperitoneal (i.p.) injections of poly-(I:C) (Invivogen) at 2-day intervals[@R21],[@R51]. Littermate male Mx1-cre^--^α~4~^f/f^ mice (Cre^--^α~4~^f/f^) that also received identical treatments with poly-(I:C) served as controls. The mice were fed a normal-fat diet (D12450B, 10% of Kcal from fat, Research Diets) or a high-fat diet (HFD; D12492, 60% of Kcal from fat, Research Diets) for up to 20 weeks starting at 2 weeks after Cre-recombinase induction. Deletion of α~4~ integrin was confirmed by examining α~4~ integrin expression by flow cytometry (anti-CD49d, PS/2, AbD Serotec) in leukocytes isolated from blood upon Ficoll gradient purification (GE Healthcare). Mice with *Itgal* deletion (α~L~ integrin KO) were previously described[@R52]. B6.V-*Lep*^ob^/JRj (ob/ob) mice were from Janvier Labs. Animal experiments were approved by the Landesdirektion Sachsen, Germany.

In the α~4~ integrin inhibitor experiments, male C57BL/6 mice (Charles River) were fed a HFD for at least 6 weeks before subcutaneous implantation of an Alzet osmotic pump (Alzet, model 2006) filled with vehicle (PBS) or α~4~-inhibitor (α~4~-inh.; 69.125 μM in a 200 μl-total volume in the pump) allowing for continuous release for 6 weeks. Thereafter, mice were fed a HFD for another 6 weeks. The ob/ob mice were implanted with an Alzet osmotic pump including PBS or α~4~-inhibitor at week 6 of their age. The α~4~ integrin inhibitor ELND002, which has been previously used in clinical trials (NCT01318421 and NCT01144351), preferentially blocks α~4~β~1~ integrin (as compared to α~4~β~7~ integrin) and efficiently inhibits the α~4~β~1~--VCAM-1 interaction[@R53] is described in detail in patent US 8,269,009 B2, and was provided by Elan Pharmaceuticals and Biogen Idec.

In thermoneutrality experiments, male C57BL/6 mice were fed a HFD for a total of 8 weeks. After 4 weeks of feeding, the mice were implanted with an Alzet osmotic pump, delivering α~4~-inhibitor or vehicle. After pump implantation each group of mice (α~4~-inh. or PBS) was divided into two subgroups and the feeding was continued for another 4 weeks under ambient (22°C) or thermoneutrality (30°C) conditions. In cold exposure experiments, obese mice were challenged with a temperature of 4°C with free access to water and food for 12 h. Thereafter, tissues were harvested and snap frozen in liquid nitrogen for RNA and protein analysis or fixed in 10% formalin for histology.

An estimate of at least 4-6 mice/group was used in experiments. No blinding was performed. In the osmotic pump experiments, groups were weight matched and randomized to the two different treatments. Pre-established exclusion criteria included death of a mouse or requirement of euthanasia of a mouse following animal protocol-defined endpoints (for instance signs of systemic illness or other forms of distress) prior to completion of the experiment. According to these predefined criteria, exclusion was necessitated in one experiment involving overall one mouse. One mouse from the 30°C α~4~-inh. group (involving the assays shown in [Fig. 5d,e](#F5){ref-type="fig"}) was excluded according to these pre-established criteria.

Monocyte and T cell trafficking assays {#S12}
--------------------------------------

Mouse bone marrow monocytes or splenic T cells were isolated from Cre^--^α~4~^f/f^ and Cre^+^α~4~^f/f^ mice after induction of Cre recombinase by using a mouse monocyte enrichment kit (EasySep) or a Pan T cell isolation kit II (Miltenyi Bitotec). Cell purity was confirmed by flow cytometry; monocytes were defined as CD11b^+^Ly6G^--^ cells and T cells as CD45^+^CD3^+^ cells (anti-Ly6G, 1A8 from BD; anti-CD11b, M1/70 from Biolegend; anti-CD45, 30-F11 from BD; anti-CD3, 145-2C11 from eBioscience). Monocyte or T cell labeling and trafficking were performed as described with modifications[@R54]. Cre^--^α~4~^f/f^ and Cre^+^α~4~^f/f^ monocytes or T cells were labeled with PKH26red and PKH67green, respectively, by using the PKH26- or PKH67-fluorescent cell linker kits (Sigma Aldrich). Isolated monocytes or T cells were washed with PBS and resuspended in 1 ml diluent solution C (included in the aforementioned kit). One ml of PKH26 or PKH67 (4 μM in diluent C per 2 × 10^7^ cells) was finally added and the cells were incubated for 5 min at 22°C in dark. The staining was halted by adding 2 ml FBS and cells were washed in medium supplemented with 10% FBS. A combination of equal numbers of PKH26- and PKH67-labeled cells (2.9 × 10^6^ cells) was simultaneously injected into DIO C57BL/6 male mice (fed a HFD up to 20 weeks). Seven days thereafter, the labeled cells, located in the inguinal subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) or draining lymph nodes (inguinal lymph nodes for SAT, mesenteric lymph nodes for VAT), were analyzed by flow cytometry; in some cases analysis also included additional staining for identification of macrophages (anti-F4/80, BM8 from eBioscience and anti-CD11b) and T cells (anti-CD3).

Metabolic phenotyping {#S13}
---------------------

Blood glucose, cholesterol and triglycerides were measured in blood samples of overnight fasted mice with a glucose meter device (Accu-Chek, Roche) and the Accutrend Plus system (Roche). Fasting insulin concentrations were measured with an ELISA Kit (Crystal Chem). For insulin tolerance tests (ITT), mice were fasted for 6 h and then injected i.p. with insulin (1--1.5 U/Kg, Huminsulin, Lilly). Glucose concentrations were measured at specific time points up to 120 min after insulin injection.

For metabolic cage analysis[@R55], mice fed a HFD for 8 weeks were individually housed in metabolic chambers (PhenoMaster, TSE Systems) with free access to food and water, maintaining a 12 h : 12 h dark--light cycle. Mice were acclimatized in metabolic chambers for 24 h before initiation of data collection. The volume of oxygen consumption (VO~2~) and carbon dioxide production (VCO~2~) were determined every 20 min for a period of 3 days. Respiratory exchange ratio (RER) was defined as VCO~2~/VO~2~ and energy expenditure (EE) was determined by using the formula 3.941×VO~2~ + 1.106×VCO~2~; food uptake was also determined. Statistics were performed using ANCOVA analysis. Determination of lean and fat mouse mass was performed by using computed tomography (CT, Skyscan 1178; Bruker)[@R56].

3T3-L1 cell culture {#S14}
-------------------

Mouse 3T3-L1 preadipocytes (ATCC) were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with penicillin-streptomycin and 10% heat-inactivated fetal calf serum (FBS) (Gibco-BRL). Cells were tested negative for mycoplasma. For differentiation to adipocytes, medium was replaced with complete DMEM containing insulin (1 μg/ml, Sigma Aldrich), 3-isobutyl-1-methylxantine (0.5 mM, Sigma Aldrich) and dexamethasone (0.25 μM, Sigma Aldrich) starting 2 days after reaching confluence (day 0). On day 3, the medium was replaced every other day with complete DMEM containing insulin (1 μg/ml). Fully differentiated 3T3-L1 adipocytes (day 8--10) were used for assays. In some experiments, 3T3-L1 adipocytes were stimulated with mouse TNF (20 ng/ml, R&D) or palmitate-BSA (250 μM, Sigma Aldrich) prior to further analysis.

Primary pre-adipocyte isolation and adipocyte differentiation {#S15}
-------------------------------------------------------------

Mouse primary adipocyte differentiation was performed as described with modifications[@R8],[@R57]. For isolation of stromal vascular (SV) cells, SAT of lean male C57BL/6 mice was dissected, minced, digested for 60 min at 37°C in PBS containing 0.5% BSA (Sigma Aldrich), collagenase I (2 mg/ml, Gibco) and 10 mM CaCl~2~, filtered through a 40-μm cell strainer and centrifuged at 600*g* for 5 min. SV cells were resuspended in DMEM/F12 medium supplemented with 10% FBS, glutamax and penicillin-streptomycin and filtered through a 40-μm cell strainer. Afterwards, the SV cells underwent a CD45 negative selection to remove hematopoietic cells using MACS magnetic beads (Miltenyi) and were plated into 6-well plates. After 90 min, SV cells were washed twice with PBS, to remove non-adherent cells and then were grown to 70-80% confluence in complete DMEM/F12. For SV cell differentiation to adipocytes, SV cells were seeded into 24-well plates at a density of 5 × 10^4^ cells per well in 1 ml complete DMEM/F12. When reaching confluence (day 0), cell medium was replaced with medium containing insulin (1 μg/ml, Sigma Aldrich), 3-isobutyl-1-methylxantine (0.5 mM, Sigma Aldrich), dexamethasone (0.25 μM), pioglitazone (1 μM, Sigma Aldrich), and T3 (1 nM, Sigma Aldrich). After 48 h, medium was exchanged (every 2 days) with complete DMEM/F12 containing insulin (1 μg/ml), T3 (1 nM) and pioglitazone (1 μM). Differentiated adipocytes (day 8-10) were used for assays. In some experiments, adipocytes were stimulated with mouse TNF (10 ng/ml) or palmitate-BSA (250 μM) prior to analysis.

Co-cultures of macrophages with primary adipocytes or adipocyte progenitors {#S16}
---------------------------------------------------------------------------

Primary bone marrow derived macrophages (BMDMs) were prepared by flushing the bone marrow of C57BL/6 mice[@R26],[@R58]. After performing red blood cell (RBC) lysis, cells were grown in RPMI-1640 supplemented with 10% FBS, glutamax, penicillin-streptomycin, and recombinant murine GM-CSF (10 ng/ml, PeproTech) for 7 days. GM-CSF-cultured BMDMs were stimulated with LPS (100 ng/ml; Invivogen) for 12 h to induce an inflammatory M1-like phenotype. BMDMs were harvested by using a non-enzymatic cell dissociation solution (Sigma Aldrich) and were counted before co-culturing with adipocytes.

Primary pre-adipocytes isolated from the SV of the SAT undergoing differentiation (see previous paragraph) were treated on day 8 or 9 of their differentiation with T3 (10 nM) and norepinephrine (1 μM; Sigma Aldrich) for 3 h, to induce a thermogenic response[@R34] and then washed before co-culturing with BMDMs. For direct primary adipocyte--BMDM co-cultures, in which the cells were in contact with each other, adipocytes were cultured without or with BMDMs (5 × 10^4^) for 1 h. Experiments were performed in the absence or presence of the α~4~-inhibitor (ELND002; 1 nM). In other experiments, adipocytes were pre-treated with an Erk inhibitor (UO126, 10 μM, Sigma Aldrich) for 30 min and washed with medium prior to addition of M1-like polarized BMDMs. For adipocyte mRNA expression analysis, cells were trypsinized, washed with PBS and separated from macrophages by performing CD45 negative selection using MACS magnetic beads (Miltenyi). *Ucp1* mRNA expression was analyzed by qPCR; *18S* was used for normalization.

For protein detection of phospho-Erk1/2 and phospho-p38 in adipocytes after co-cultures with macrophages for 30 min, cells were harvested by trypsinization, washed with PBS and incubated with mouse Fc block and a rat anti-mouse APC-conjugated CD11b antibody (M1/70) (both from BD) for 15 min on ice. After fixation with 4% paraformaldehyde for 10 min, cells were permeabilized by using 90% methanol, treated with 10% goat serum (Sigma Aldrich) and incubated with either rabbit anti-mouse phospho-p44/42 MAPK (pErk1/2, Thr202/Tyr204) antibody (0.5 μg/100 μl; Cell Signaling; catalog \# 9101), or rabbit anti-mouse phospho-p38 MAPK (Thr180/Tyr182) antibody (0.25 μg/100 μl; Cell Signaling, catalog \# 4511) for 1 h at 22°C. After washing, cells were incubated with goat anti-rabbit IgG (H+L) Alexa fluor 488 (0.1 μg/100 μl; Invitrogen; catalog \# A-11034) for 1 h at 22°C. Median fluorescence intensity (MFI) was determined by flow cytometry (FACS Canto II, BD) after gating of adipocytes (defined as CD11b-negative cells).

In other experiments, co-cultures of adipocytes were performed with SAT-derived macrophages. For isolation of primary macrophages from SAT, SV cells were isolated from lean mice or obese C57BL/6 mice. Isolated SV cells were stained with anti-F4/80 Microbeads (Miltenyi Biotec) and macrophages were selected as F4/80^+^ cells by using MACS columns. The isolated macrophages were cultured in complete RPMI 1640 medium with M-CSF (10 ng/ml, eBioscience) for 24 h. To obtain M1-like polarized macrophages, obese SAT-derived macrophages were additionally treated with LPS (100 ng/ml, Invivogen) and IFN-γ (20 ng/ml, BD) for 12 h, while for obtaining M2-like polarized macrophages, lean SAT-derived macrophages were treated with IL-4 (20 ng/ml, PeproTech) for 12 h.

In direct primary adipocyte--SAT-derived macrophages co-cultures, adipocytes, pre-treated with T3 and norepinephrine, were co-cultured without or with SAT-derived M1-like polarized macrophages (2 × 10^4^ cells) for 1 h, as described above for adipocyte-BMDM co-cultures. In other experiments, adipocytes were co-cultured without or with SAT-derived M2-like polarized macrophages (2 × 10^4^ cells) for 6 h. Experiments were performed in the absence or presence of the α~4~-inhibitor (1 nM). The cells were trypsinized, and *Ucp1* mRNA expression in adipocytes was analyzed by qPCR after their separation as CD45-negative cells by using MACS magnetic beads (Miltenyi Biotec).

The indirect primary adipocyte--primary SAT-derived macrophages co-cultures, in which the cells were not in contact, were performed by using 0.4-μm pore size Transwell inserts (Corning). T3 and norepinephrine pre-treated primary adipocytes (lower compartment), were co-cultured for 6 h without or with SAT-derived M2-like polarized macrophages (2 × 10^4^ cells) that were in the Transwell inserts, in the absence or presence of the α~4~-inhibitor. At the end of the experiment, Transwell inserts were removed, adipocytes were washed and *Ucp1* mRNA expression was analyzed by qPCR.

In other experiments, M1- or M2-like polarized SAT-derived macrophages were seeded on 0.4-μm pore size Transwell inserts (0.4-μm pore size) at a density of 2 × 10^4^ cells and co-cultured with primary adipocytes. The experiments with M2-like macrophages were performed in the absence or presence of the α~4~-inhibitor. In the case of M1-like macrophages, experiments were performed in the absence or presence of a TNF-blocking antibody (1 μg/ml, R&D; catalog \# AF-410-NA). After incubating for 24 h, adipocytes were trypsinized and stained with an anti-VCAM-1 antibody (clone 429, BD); VCAM-1 expression was analyzed by flow cytometry.

For adipocyte progenitor cell isolation, SV cells from SAT from lean C57BL/6 mice were washed with PBS containing 0.5% BSA (Sigma Aldrich), incubated with Fc block (BD) and stained with anti-CD31 (MEC 13.3 from BD), anti-CD45 (30-F11 from Biolegend), anti-Sca1 (D7 from BD), and anti-PDGFRα (APA5 from BD) for 20 min at 4°C. Adipocyte progenitors were sorted as CD31^--^CD45^--^Sca1^+^PDGRα^+^ cells in a FACS Aria II cell sorter (BD). The cells were seeded into culture dishes until reaching 70-80% confluence and then transferred to 24-well plates (5 × 10^4^ cells/well) before co-culturing with BMDMs. Specifically, after 3 h pre-treatment of adipocyte progenitors with T3 and norepinephrine, direct co-cultures of adipocyte progenitors with M1-like polarized BMDMs were performed for 1 h in the absence or presence of the α~4~-inhibitor. Thereafter, *Ucp1* mRNA abundance in adipocyte progenitors was determined by qPCR, after exclusion of BMDMs as described above. In other experiments, after isolation of SV cells and adipocyte progenitor cell sorting, the latter were seeded for 24 h in 48-well plates (2 × 10^4^ cells/well), then treated overnight with mouse recombinant TNF (20 ng/ml, R&D systems) and mRNA expression of *Vcam1* was analyzed by qPCR.

Isolation of mature adipocytes, adipocyte progenitors and endothelial cells from AT {#S17}
-----------------------------------------------------------------------------------

SAT, VAT and BAT from lean or obese C57BL/6 mice were digested with collagenase and filtered. After centrifugation, the floating cells representing the mature adipocytes were collected, washed 3x with PBS and RNA isolation was performed with Trizol. The SV cells in the pellet were washed with PBS containing 0.5% BSA and then incubated with Fc block (BD) and stained with anti-CD31 (MEC 13.3 from BD), anti-CD45 (30-F11 from BioLegend), anti-Sca1 (D7 from BD), and anti-PDGFRα (APA5 from BD) antibodies for 20 min at 4°C. After washing, CD31^--^CD45^--^Sca1^+^PDGRα^+^ adipocyte progenitors or CD45^--^CD31^+^ endothelial cells were sorted in a FACS Aria II cell sorter (BD) and RNA from each individual population was isolated by using Trizol.

Stromal vascular fraction (SVF) isolation and flow cytometry {#S18}
------------------------------------------------------------

SVF was prepared as reported[@R55],[@R59],[@R60]. Briefly, inguinal SAT or VAT were isolated from euthanized mice, minced and digested for 60 min in DMEM containing collagenase type I (2 mg/ml per gram of tissue; Invitrogen) at 37°C. Cell suspensions were then filtered through a 40-μm cell strainer and the SVF was collected as a pellet after centrifugation at 500*g* for 5 min. After RBC lysis, cells were stained with anti-CD45 (30-F11, BD), anti-F4/80 (clone BM8, BioLegend), anti-CD11b (M1/70, BD), anti-CD11c (HL3, BD), anti-CD206 (c06802, BioLegend; MR5D3, Acris), anti-TNF (MP6-XT22, BioLegend), anti-iNOS (CXNFT, eBioscience) and anti-CD49d \[clone PS/2, AbD Serotec or clone 9C10(MFR4.B), BioLegend\]. Cells were analyzed in a FACS Canto II flow cytometer (BD).

Histological analysis {#S19}
---------------------

For immunohistochemistry, AT were fixed overnight in 10% formalin solution, embedded in paraffin and cut into 5-μm sections[@R59]. For adipocyte size determination, images of H&E-stained SAT or VAT sections were obtained and the diameter of \~ 200 adipocytes per slide was measured with the AxioVision Rel. 4.8 software (Carl Zeiss MicroImaging). The diameters of both height and width were measured from each cell. For UCP1 or F4/80 immunohistochemistry, sections were de-paraffinized and incubated with pronase (Sigma Aldrich) or citrate buffer, respectively. Sections were then incubated overnight with antibody against UCP1 (Abcam; catalog \# ab10983) or F4/80 (Novus Biologicals; catalog \# NB600-404). The Vectastain ABC kit (Vector Laboratories) was used for UCP1 or F4/80 detection. Images were obtained by a computerized microscope (Zeiss) or an Axioscan.Z1 slide scanner (Zeiss). Quantification of CLS numbers was performed in whole-section F4/80-stained mosaic images by counting the number of CLS per mm^2^ of tissue in 6 sections per sample. Determination of non-CLS-associated macrophage numbers was performed by counting the number of F4/80 positive cells per 100 adipocytes from 10 random low-magnification CLS-free fields per sample. The Zen Imaging Software (Zeiss) was used in both types of quantification.

For immunofluorescence detection of macrophages (F4/80 staining) and adipocytes (caveolin-1 staining)[@R6],[@R28] in SAT, whole mounts were prepared. The tissues were extracted and fixed with paraformaldehyde 4% (Thermo Fisher Scientific) for 2 h at 4°C. Thereafter, the tissue was cut into small cubic pieces (each side approximately 2 mm). The samples were thoroughly washed with PBS and blocked-permeabilized in serum-free protein block (Dako) with 1% Saponin (Sigma Aldrich) for 2 h at 22°C. The primary antibody incubation was performed in Antibody diluent (Dako) supplemented with 0.5% Saponin overnight at 4°C. A rat anti-mouse F4/80 (1:100, CI:A3-1; Abcam, ab6640) and a rabbit anti-mouse caveolin-1 (1:100, Abcam, ab192869) were used. After washings, incubation with appropriate fluorescently-labeled secondary antibodies (from Jackson Immunoresearch and Thermo Scientific) and counterstaining with DAPI (1:2000, Sigma Aldrich), images were acquired with a Zeiss LSM 510 confocal microscope (Zeiss). For the 3D reconstruction of macrophage-adipocyte interactions in the SAT, the Arivis Vision 4D software was used.

For the quantification of the contact area between macrophages and adipocytes in SAT, images were acquired with an Olympus IX83 microscope equipped with a Yokogawa CSU-X1 spinning disc confocal scanner (Olympus). Quantification was performed with the Fiji software[@R61] and its update SCF-MPI-CBG (<http://sites.imagej.net/SCF-MPI-CBG/>) by analyzing 10 arbitrarily selected cells per mouse. Annotation of the contact surface between macrophages (F4/80 positive cells - green) and adipocytes (caveolin-1 positive cells - red) was done by manually drawing lines along the surface plane by plane in the Fiji software. The surface area was then calculated by a custom tool (SCF-MPI-CBG), which interpolated the surface area from the drawn lines.

Analysis of human *VCAM1* and *UCP1* mRNA expression in adipose tissue {#S20}
----------------------------------------------------------------------

Paired samples of subcutaneous whole AT were obtained from 169 individuals (113 women and 56 men). The age ranged from 19 to 88 years and the BMI from 18.8 to 73.2 kg/m². Phenotypic characterization of the study participants was reported[@R62]. All AT samples were collected during open or laparoscopic abdominal surgery as described[@R62]. The study was approved by the Ethics Committee of the University of Leipzig (approval no: 159-12-21052012 and 017-12-23012012), and performed in accordance to the declaration of Helsinki. All subjects gave written informed consent before taking part in this study.

AT was immediately frozen in liquid nitrogen and stored at -80°C. RNA was extracted from AT by using RNeasy Lipid tissue Mini Kit (Qiagen). Quantity and integrity of RNA was monitored with NanoVue plus Spectrophotometer (GE Healthcare). One µg total RNA from subcutaneous AT was reverse-transcribed with standard reagents (Life technologies). cDNA was then proceeded for TaqMan probe-based quantitative real-time polymerase chain reaction (qPCR) using the QuantStudio 6 Flex Real-Time PCR System (Life Technologies). Human *VCAM1* and *UCP1* expression were measured by quantitative real-time RT-PCR using the following probes: human *VCAM1* (Hs01003370_m1, ThermoFisher Scientific), *UCP1* (Hs00222453_m1, ThermoFisher Scientific). Fluorescence emissions were monitored after each cycle. Human *VCAM1* and *UCP1* mRNA expression were calculated relative to the mRNA expression of *hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1)* (Hs01003267_m1, ThermoFisher Scientific). For correlation analysis (as presented in [Fig. 7g](#F7){ref-type="fig"}) only samples with detectable *UCP1* expression were utilized, as *UCP1* expression was detectable only in a subset of the AT samples.

Statistical analysis {#S21}
--------------------

Statistical tests used are indicated in figure legends. For statistical comparisons, data were analyzed by a Student's t-test or a Mann-Whitney U test, as appropriate. One-tailed Pearson correlation analysis was performed to examine the association between *VCAM1* and *UCP1* expression in human AT samples. For metabolic cage analysis, a one-way analysis of covariance (ANCOVA) was conducted in conjunction with a Bonferroni post-hoc test. The body weight was used as the covariate. The Graph Pad Prism 6 or the IBM SPSS statistics 22 were used. Significance was set at *P* \< 0.05.

Supplementary Material {#SM}
======================

**The Supplementary Information contains additional Methods (Cell adhesion assays, Macrophage activation studies, Experiments with human cells, Immunoblot, Real-Time PCR)**.
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![The α~4~ integrin--VCAM-1 interaction mediates direct macrophage-adipocyte interactions.\
**a-c)** Adoptive transfer experiments; a 1:1 mixture of PKH26-red labeled Cre^-^α~4~^f/f^ and PKH67-green labeled Cre^+^α~4~^f/f^ cells (monocytes or splenic T cells) was simultaneously transferred into obese wild-type mice. The numbers of Cre^-^α~4~^f/f^ and Cre^+^α~4~^f/f^ macrophages (**a**) or T cells (**c**) accumulated in inguinal subcutaneous adipose tissue (SAT) or visceral adipose tissue (VAT) and the numbers of Cre^-^α~4~^f/f^ and Cre^+^α~4~^f/f^ monocytes/macrophages accumulated in the lymph nodes draining the SAT (SAT dLN) and lymph nodes draining the VAT (VAT dLN) (**b**) were analyzed by flow cytometry. Data (percentage of labeled cells in defined cells) are presented as relative to control. The percentage of labeled Cre^-^α~4~^f/f^ cells in defined cells was set as 100% in each tissue; n=5 recipient mice in **a,b** and n=4 recipient mice in **c**; data in (**b**) are from one experiment, data in (**a**), (**c**) are representative of two experiments. **d)** *Vcam1* mRNA expression was determined in VAT and SAT of lean mice, fed a normal diet (ND, n=8 mice) or obese mice (fed a HFD, n=10 mice), in mature adipocytes from VAT and SAT of lean (ND, n=6 mice) or obese mice (HFD, n=6 mice), and in CD31^+^ endothelial cells from SAT of lean (ND, n=5 mice) or obese mice (HFD, n=6 mice). *18S* expression was used for normalization and *Vcam1* expression of ND-fed mice was set as 1 in each case. Data are from one experiment (SAT endothelial cells) or representative of two experiments (VAT, SAT, VAT adipocytes, SAT adipocytes). (**e**) Comparison of *Vcam1* mRNA expression between CD45^-^CD31^+^ endothelial cells and adipocytes from SAT of obese mice is shown. *Vcam1* expression of endothelial cells was set as 1; n=6 mice; data are from one experiment. **f)** Primary mouse adipocytes were treated without (control; Con) or with TNF or palmitate. The surface expression of VCAM-1, expressed as Median Fluorescence Intensity (MFI) units, analyzed by flow cytometry, is shown (n=6 separate cell isolations; data are representative of two experiments). In the right panel, a representative flow cytometry plot depicting VCAM-1 expression of Control-, TNF-, or palmitate-treated adipocytes, as well as isotype control (Iso), is shown. **g)** Adhesion assay of bone marrow mononuclear cells (BMM) to TNF- or palmitate-pretreated 3T3-L1 adipocytes was performed in the presence of ICAM-1- or VCAM-1-blocking antibodies or respective isotype controls (ICAM-1 Iso or VCAM-1 Iso). The percentage of adherent cells is shown. Shown is one experiment performed in triplicate; representative of 3 experiments. **h)** Adhesion of BMM from Cre^+^α~4~^f/f^ or Cre^-^α~4~^f/f^ mice to TNF- or palmitate-pretreated 3T3-L1 adipocytes (data from separate BMM isolations from n=6 Cre^+^α~4~^f/f^ mice and n=8 Cre^-^α~4~^f/f^ mice; pooled from 3 experiments). The percentage of adherent cells is shown.\
Data are presented as mean ± SEM. \*P \< 0.05. Mann-Whitney U-test in (**a**), (**c**), (**d**), (**e**), (**f**), Student\'s t-test in (**b**), (**g**), (**h**).](emss-72016-f001){#F1}

![Deficiency of α~4~ integrin ameliorates macrophage accumulation in obese AT and alleviates obesity-associated insulin resistance.\
**a)** Body weight of Cre^+^α~4~^f/f^ (n=14 mice) or Cre^-^α~4~^f/f^ (n=15 mice) mice fed a HFD. **b)** Lean and fat mass of Cre^+^α~4~^f/f^ (n=6 mice) and Cre^-^α~4~^f/f^ (n=6 mice) mice were determined by micro-CT at the end of the feeding period. **c)** Insulin tolerance test (ITT) of obese Cre^+^α~4~^f/f^ (n=14 mice) or Cre^-^α~4~^f/f^ (n=15 mice) mice. **d)** Data obtained from ITT (**c**) are also presented as area under the curve (AUC). Data are presented as relative to control (Cre^-^α~4~^f/f^ mice), which was set as 100%. **e-f**) Representative confocal microscopy images of SAT from obese Cre^+^α~4~^f/f^ or Cre^-^α~4~^f/f^ mice. Crown like structures (CLS) (**e**) and non-CLS-associated macrophages (**f**) in SAT are shown by staining for macrophages (F4/80, green), adipocytes (caveolin-1, red) and nuclei (DAPI, blue). **g-h)** Stromal vascular fraction (SVF) cells from (**g**) SAT (n=7 mice for Cre^+^α~4~^f/f^ and n=4 mice for Cre^-^α~4~^f/f^) and (**h**) VAT (n=7 mice for Cre^+^α~4~^f/f^, and n=5 mice for Cre^-^α~4~^f/f^) of obese Cre^+^α~4~^f/f^ and Cre^-^α~4~^f/f^ mice were isolated and analyzed by flow cytometry. M1-like pro-inflammatory macrophages (M1MΦ) were defined as F4/80^+^CD11b^+^CD206^-^iNOS^+^ and M2-like anti-inflammatory macrophages (M2MΦ) were defined as F4/80^+^CD11b^+^CD206^+^iNOS^-^. Data are presented as relative to control; the numbers of M1MΦ/gram tissue or M2MΦ/gram tissue from Cre^-^α~4~^f/f^ mice were set as the 100% control in each case. **i-j**) TNF expression of macrophages in (**i**) SAT (n=7 mice for Cre^+^α~4~^f/f^ and n=4 mice for Cre^-^α~4~^f/f^) and (**j**) VAT (n=7 mice for Cre^+^α~4~^f/f^, and n=5 mice for Cre^-^α~4~^f/f^) of obese Cre^+^α~4~^f/f^ and Cre^-^α~4~^f/f^ mice was analyzed by flow cytometry. Data (percentage of TNF-positive macrophages, defined as CD45^+^F4/80^+^CD11b^+^ cells) are presented as relative to control (Cre^-^α~4~^f/f^ mice) which was set as 100%. **k)** The SVF from SAT and VAT of obese wild type mice (n=4 mice) was prepared and the amount of α~4~ integrin, expressed as MFI units, was determined by flow cytometry in M1-like (F4/80^+^CD11b^+^CD206^-^iNOS^+^) or M2-like (F4/80^+^CD11b^+^CD206^+^iNOS^-^) macrophages.\
Data are presented as mean ± SEM. Data in (**a**), (**c**) and (**d**) are pooled from 5 experiments; data in (**b**) are pooled from 2 experiments; data in (**g**), (**h**), (**i**), (**j**) are representative of 2 experiments; data in (**k**) are from one experiment. In (**e**) and (**f**) representative images are from analysis performed on 3-4 mice per genotype. \*P \< 0.05. Student\'s t-test in (**a**) -- (**d**) and (**h**), Mann-Whitney U-test in (**g**), (**i**), (**j**), (**k**).](emss-72016-f002){#F2}

![Deficiency of α~4~ integrin promotes beige adipogenesis of white AT in obesity.\
**a)** Energy expenditure (EE, expressed as kcal/h) of obese Cre^+^α~4~^f/f^ (n=4 mice) and Cre^-^α~4~^f/f^ (n=5 mice) mice was assessed by a metabolic cage monitoring system for 3 days (left). Average EE in light and dark period is also displayed (right). **b)** Gene expression in SAT of obese Cre^+^α~4~^f/f^ or Cre^-^α~4~^f/f^ mice was evaluated by qPCR (n=8 mice for Cre^+^α~4~^f/f^ and 10-11 mice for Cre^-^α~4~^f/f^). *18S* expression was used for normalization of mRNA expression and the respective gene expression of obese Cre^-^α~4~^f/f^ mice was set as 1. **c)** Representative cropped blot images showing immunoblotting for UCP1 (and actin) in SAT from 2 obese Cre^+^α~4~^f/f^ and 2 Cre^-^α~4~^f/f^ mice. Actin was used as loading control. **d-f)** Obese Cre^+^α~4~^f/f^ or Cre^-^α~4~^f/f^ mice were challenged with a temperature of 4°C for 12 h. **d)** Core temperature of obese Cre^+^α~4~^f/f^ (n=4 mice) or Cre^-^α~4~^f/f^ (n=6 mice) mice during cold exposure. **e)** Representative cropped blot images showing immunoblotting (left) for UCP1 (and actin) in SAT of 2 obese Cre^+^α~4~^f/f^ and 2 obese Cre^-^α~4~^f/f^ mice exposed to cold. Densitometric analysis (right) of UCP1 immunobloting from a total of 4 Cre^+^α~4~^f/f^ mice and 5 Cre^-^α~4~^f/f^ mice is shown. The protein amounts of UCP1 were normalized against actin; the UCP1 amounts (normalized over actin) in SAT from Cre^-^α~4~^f/f^ mice were set as 1. **f)** UCP1 staining in SAT from Cre^+^α~4~^f/f^ or Cre^-^α~4~^f/f^ mice exposed to cold. **g)** Mature white and brown adipocytes were isolated from SAT and BAT of obese mice (n=6 mice) after tissue digestion and *Vcam1* mRNA expression was determined. *18S* expression was used for normalization and *Vcam1* expression of SAT was set as 1.\
Data are presented as mean ± SEM. Data in (**a**), (**d**) and (**e**) are from one experiment; data in (**b**) are pooled from 3 experiments; data in (**c**) and (**g**) are representative of 2 experiments. In (**f**) representative images are from analysis performed on 5 Cre^-^α~4~^f/f^ and 4 Cre^+^α~4~^f/f^ mice. \*P \< 0.05. ANCOVA in (**a**) and Mann-Whitney U-test in (**b**) -- (**g**).\
Abbreviations: *Ucp1*, uncoupling protein 1; *Cidea*, cell death-inducing DNA fragmentation factor-like effector A; *Cox8b*, cytochrome c oxidase subunit 8b; *Cox7a1*, Cytochrome c oxidase subunit 7A1; *Acsl1*, acyl-CoA synthetase long-chain family member 1](emss-72016-f003){#F3}

![Pharmacologic inhibition of α~4~ integrin ameliorates obesity-related metabolic dysregulation and enhances beige adipogenesis in SAT.\
After establishment of DIO, C57BL/6 mice were implanted with an Alzet osmotic pump for continuous administration of α~4~-inhibitor (α~4~-inh.) or vehicle (Con) for 6 more weeks. **a)** Left: Insulin tolerance test (ITT) of control- (n=10 mice) or α~4~-inhibitor-treated (n=9 mice) mice 5 weeks after pump implantation. Right: Data obtained from ITT are presented as area under the curve (AUC); data are presented as relative to control (Con) which was set as 100%. **b-c)** Fasting plasma insulin (**b**), fasting blood glucose (Glu), triglyceride (TG), and cholesterol (Chol) (**c**) from control- (n=10 mice) or α~4~-inhibitor-treated (n=9 mice) mice were measured at the end of the feeding. **d)** Confocal microscopy images of SAT from α~4~-inhibitor (α~4~-inh.)- or vehicle (Con)-treated mice. Non-CLS-associated macrophages in SAT are shown by staining for macrophages (F4/80, green) and adipocytes (caveolin-1, red). **e)** Quantification of CLS numbers and of non-CLS-associated macrophages in SAT from α~4~-inhibitor (α~4~-inh, n=5 mice)- or vehicle- (Con, n=5 mice)-treated mice in sections stained immunohistochemically for F4/80. Shown are the number of CLS per 100 mm^2^ of tissue and the number of non-CLS-associated macrophages per 100 adipocytes. **f**) The stromal vascular fraction (SVF) from SAT of control- (n=4 mice) or α~4~-inhibitor-treated (n=5 mice) obese wild-type mice was isolated 6 weeks after pump implantation and pro-inflammatory M1-like macrophages (M1MΦ, F4/80^+^CD11b^+^CD206^-^iNOS^+^) and M2-like anti-inflammatory macrophages (M2MΦ, defined as F4/80^+^CD11b^+^CD206^+^iNOS^-^) were analyzed by flow cytometry. Data are presented as relative to control; the numbers of M1MΦ/gram tissue or M2MΦ/gram tissue from control-treated mice were set as the 100% control in each case.\
Data are presented as mean ± SEM. Data in (**a**)-(**c**) and (**e**)-(**f**) are from one experiment. In (**d**) representative images are from analysis performed on 3 mice per treatment group. \*P \< 0.05. Student\'s t-test in (**b**), (**e**) and Mann-Whitney U-test in (**a**), (**c**), (**f**).](emss-72016-f004){#F4}

![UCP1 is essential for the beneficial effects of pharmacological inhibition of α~4~ integrin on beige adipogenesis.\
**a-b**) After establishment of DIO, C57BL/6 mice were treated with α~4~-inhibitor (α~4~-inh.) or vehicle (Con) for 6 more weeks. **a)** Expression of mRNA of thermogenesis-related genes in SAT of control- or α~4~-inhibitor-treated mice (n=6 mice per group). *18S* expression was used for normalization and the respective gene expression of control-treated mice was set as 1. **b)** Representative cropped blot images showing immunoblotting (left) of UCP1 (and actin) in SAT of 3 control- and 3 α~4~-inhibitor-treated mice. Densitometric analysis (right) of UCP1 immunoblotting from a total of 6 control- and 6 α~4~-inhibitor-treated mice is shown. The protein amounts of UCP1 were normalized against actin; the UCP1 amounts (normalized over actin) in SAT from control-treated mice were set as 1. **c-f**) After 4 weeks on HFD, wild-type C57BL/6 mice were implanted with an Alzet osmotic pump, delivering α~4~-inhibitor (α~4~-inh.) or vehicle (Con). After pump implantation, each group of mice (α~4~-inh. or Con) was divided into two subgroups and the feeding was continued for another 4 weeks at 22°C or 30°C (thermoneutrality). **c-d)** Insulin tolerance tests (ITT) from mice 4 weeks after pump implantation are shown (n=6 mice/group and n=8 mice/group for 22°C and 30°C, respectively). **e)** The mRNA expression of thermogenic genes in SAT of α~4~-inh.-treated or control-treated mice at 22°C or 30°C was analyzed at the end of the feeding period. *18S* expression was used for normalization and the respective gene expression of control-treated mice maintained at 22°C was set as 1 (22°C - Con, n=6 mice; 22°C - α~4~-inh., n=6 mice; 30°C - Con, n=8 mice; 30°C - α~4~-inh., n=8 mice). **f**) The SVF from SAT and VAT of control- or α~4~-inhibitor-treated obese wild-type mice maintained under thermoneutrality conditions, was isolated at the end of the experiment and M1-like macrophages (M1MΦ, F4/80^+^CD11b^+^CD206^-^iNOS^+^) were analyzed by flow cytometry. Data are presented as relative to control; the numbers of M1MΦ/gram tissue from control-treated mice were set as the 100% control in each case (Con, n=6 mice; α~4~-inh., n=7 mice in SAT; Con, n=5 mice; α~4~-inh., n=7 mice in VAT).\
Data are presented as mean ± SEM. Data in (**a**)-(**b**) are representative of 2 experiments; data in (**c**)-(**f**) are from one experiment. \*P \< 0.05. Mann-Whitney U-test in (**a**)-(**f**).\
Abbreviations: *Ucp1*, uncoupling protein 1; *Cidea*, cell death-inducing DNA fragmentation factor-like effector A; *Cox8b*, cytochrome c oxidase subunit 8b; *Cox7a1*, Cytochrome c oxidase subunit 7A1; *Acsl1*, acyl-CoA synthetase long-chain family member 1; *Prdm16*, PR (PRD1-BF1-RIZ1 homologous)-domain containing 16](emss-72016-f005){#F5}

![α~4~ integrin-dependent macrophage-adipocyte interactions inhibit UCP1 expression in a phospho-Erk dependent manner.\
**a-b)** Primary adipocytes were cultured with T3 and norepinephrine to induce a thermogenic response, prior to co-culture in the absence or presence of (**a**) M1-like polarized pro-inflammatory BMDMs or (**b**) M1-like polarized primary SAT-derived macrophages \[M1MΦ in the figure are M1-like polarized BMDMs in (**a**) or SAT macrophages in (**b**)\] for 1 h. Co-culture was performed in direct contact (in the same well). Experiments were performed in the absence (control; Con) or presence of α~4~-inhibitor (α~4~-inh.). **a**) *Ucp1* mRNA expression was analyzed in adipocytes after separation from the BMDMs. *18S* expression was used for normalization and *Ucp1* expression in adipocytes cultured in the absence of macrophages and in the absence of α~4~-inhibitor was set as 1 (n=5 separate primary adipocyte isolations). **b**) The mRNA expression of *Ucp1* was analyzed in adipocytes after separation from SAT macrophages. *18S* expression was used for normalization and *Ucp1* expression in adipocytes cultured in the absence of macrophages and in the absence of α~4~-inhibitor was set as 1 (n=5 separate primary cell isolations from SAT). **c-d)** Primary adipocytes (pre-stimulated with T3 and norepinephrine) were co-cultured in the absence or presence of M2-like polarized primary SAT-derived macrophages (M2MΦ) in direct contact (**c**, in the same well) or in an indirect way (**d**, in transwell co-culture system, wherein adipocytes and macrophages were in the lower and upper compartment, respectively). Experiments were performed in the absence (control; Con) or presence of α~4~-inhibitor (α~4~-inh.). The mRNA expression of *Ucp1* was analyzed in adipocytes after separation from the macrophages. *18S* expression was used for normalization and *Ucp1* expression in adipocytes cultured in the absence of macrophages was set as 1 (n=5 separate primary cell isolations from SAT). **e-f)** Primary adipocytes (pre-stimulated with T3 and norepinephrine) were co-cultured in the absence (control; Con) or presence of M1-like polarized BMDMs (direct contact) for 30 min. The amounts of phospho-p38 (**e**) and phospho-Erk (**f**) in adipocytes were detected by flow cytometry. Phospho-p38 or phospho-Erk protein amounts (MFI) in adipocytes cultured in the absence of M1MΦ were set as 1 (n=4 separate primary adipocyte isolations). **g)** Primary adipocytes were pre-treated with T3 and norepinephrine for 3 h, washed and then incubated in the absence (control; Con) or presence of an Erk inhibitor for 30 min. After washing, direct co-cultures between adipocytes and M1-like BMDMs were performed for 1 h and the mRNA expression of *Ucp1* was studied in adipocytes after separation from the macrophages. The mRNA expression of *Ucp1* in the absence of BMDMs and without Erk-inhibitor pre-treatment was set as 1 (n=4 separate primary adipocyte isolations). **h, i)** T3- and norepinephrine-pre-treated adipocytes were co-cultured with M1-like BMDMs (M1MΦ) in direct contact for 30 min in the absence (control; Con) or presence of α~4~-inhibitor (α~4~-inh.). Phospho-p38 (**h**) and phospho-Erk (**i**) in adipocytes were detected by flow cytometry and their respective amount (MFI) in the presence of M1MΦ but in the absence of α~4~-inhibitor was set as 1 (n=4 separate primary adipocyte isolations). **j)** Primary adipocyte progenitor cells (AP) were isolated from SAT of wild-type C57BL/6 lean (ND, n=4 mice) and obese (HFD, n=6 mice) mice by FACS-sorting (AP cells were defined as CD31^-^CD45^-^Sca1^+^PDGFRα^+^ cells) and *Vcam1* mRNA expression was determined. *18S* expression was used for normalization and *Vcam1* expression of ND-fed mice was set as 1. **k)** AP were isolated from SVF of SAT of wild-type mice with FACS-sorting (CD31^-^CD45^-^Sca1^+^PDGFRα^+^ cells). Cells were treated without (control; Con) or with TNF. *Vcam1* mRNA expression was analyzed. *18S* expression was used for normalization and *Vcam1* expression of control-treated cells (Con) was set as 1 (n=4 separate cell isolations). **l)** AP were isolated as in (**k**) and treated with T3 and norepinephrine. Thereafter, AP were co-cultured in the absence or presence of M1-like polarized pro-inflammatory BMDMs (M1MΦ) in direct contact with each other. Experiments were performed in the absence (control; Con) or presence of α~4~-inhibitor (α~4~-inh.). The mRNA expression of *Ucp1* in AP was detected after macrophage separation. *18S* expression was used for normalization and *Ucp1* expression in the absence of macrophages and in the absence of α~4~-inh. was set as 1 (n=5 separate primary adipocyte progenitor isolations).\
Data are presented as mean ± SEM. Data in (**b**), (**c**), (**d**) are pooled from 3 experiments; data in (**a**), (**e**), (**f**), (**g**), (**h**), (**i**), (**k**) are representative of 2 experiments; data in (**j**) and (**l**) are from one experiment. \*P \< 0.05. Mann-Whitney U-test in (**a**)-(**l**).](emss-72016-f006){#F6}

![The interaction between adipocyte VCAM-1 and macrophage α~4~ integrin leads to enhanced inflammatory macrophage activation.\
**a-d**) Peritoneal macrophages were FACS-sorted from wild-type C57BL/6 mice or Cre^+^α~4~^f/f^ and Cre^-^α~4~^f/f^ mice. **a-b)** Macrophages were cultured on plates pre-coated with Fc or VCAM-1-Fc. **a)** Wild-type macrophages (n=4 separate cell isolations) were incubated on pre-coated plates for 12 h in the absence (control; Con) or presence of the α~4~-inhibitor (α~4~-inh.) and macrophage TNF expression was analyzed by flow cytometry. Data are expressed as percentage of TNF-positive macrophages (F4/80^+^CD11b^+^). **b)** Isolated Cre^+^α~4~^f/f^ (n=4 separate cell isolations) or Cre^-^α~4~^f/f^ (n=5 separate cell isolations) macrophages were incubated on plates pre-coated with Fc or VCAM-1-Fc for 6 h and TNF expression was analyzed by flow cytometry. Data are presented as percentage of TNF-positive macrophages (F4/80^+^CD11b^+^). **c-d)** Macrophages were co-cultured in a direct cell-to-cell contact mode with 3T3-L1 adipocytes for 12 h. **c)** Wild-type macrophages were co-cultured with adipocytes in the absence (control, Con) or presence of α~4~-inhibitor (α~4~-inh.) and macrophage TNF expression was analyzed by flow cytometry. Data are presented as percentage of TNF-positive macrophages (defined as CD45^+^F4/80^+^CD11b^+^) (n=4 separate macrophage isolations). **d)** Cre^+^α~4~^f/f^ or Cre^-^α~4~^f/f^ macrophages were co-cultured with adipocytes in a direct cell-to-cell contact mode and macrophage TNF expression was analyzed by flow cytometry. Data are expressed as percentage of TNF-positive macrophages (CD45^+^F4/80^+^CD11b^+^) (n=4 separate macrophage isolations). Data in (**a**)-(**d**) are representative of 2 experiments. **e-f)** Primary adipocytes were cultured in the absence or presence of M1-like or M2-like polarized SAT-derived macrophages in a transwell co-culture system (adipocytes, lower compartment; macrophages, upper compartment). The experiments were performed in the presence or absence of the α~4~-inh. or TNF-blocking antibody, as indicated. After 24 h of incubation, adipocyte VCAM-1 expression was analyzed by flow cytometry and is expressed as MFI units (n=4 separate primary cell isolations from SAT in **e** and n=5 separate primary cell isolations from SAT in **f**). Data in (**e**)-(**f**) are pooled from 2 experiments. **g)** Correlation analysis between mRNA expression of *UCP1* and *VCAM1* in human SAT (n=61 human samples). **h)** Human subcutaneous pre-adipocytes were differentiated to adipocytes and 10 days after starting differentiation were treated without (control; Con) or with TNF or palmitate for 12 h. *VCAM1* expression was analyzed and *ACTB* expression was used for normalization. *VCAM1* expression of control-treated adipocytes was set as 1. Data are pooled from 4 experiments. **i)** Human inflammatory macrophages were allowed to adhere to TNF-pre-treated differentiated human adipocytes in the absence (control; Con) or presence of α~4~-inhibitor (α~4~-inh.). The percentage of adherent cells is shown (n=4 separate macrophage isolations). Data are representative of 2 experiments. **j)** Differentiated human adipocytes were treated with T3 and norepinephrine to induce a thermogenic response, washed and then co-cultured without or with human M1-like inflammatory macrophages (M1MΦ) in the same well (direct contact) for 1 h. Experiments were performed in the absence (control; Con) or presence of α~4~-inhibitor (α~4~-inh.). The expression of *UCP1* in adipocytes (after exclusion of CD45-expressing cells) was detected; *ACTB* expression was used for normalization. *UCP1* expression in adipocytes cultured in the absence of M1MΦ and in the absence of α~4~-inhibitor was set as 1. Shown is one representative experiment (n=4-5 cell culture treatments); similar results were observed in 2 experiments.\
Data are mean ± SEM.; \*P \< 0.05. Mann-Whitney U-test was used in (**a**)-(**f**) and (**h**)-(**j**) and one-tailed Pearson Correlation analysis in (**g**).](emss-72016-f007){#F7}
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